Condition: Schizophrenia · Bipolar I Disorder · Major Depressive Disorder · Sponsor: Mapi Pharma Ltd.
The purpose of this study is to assess the PK, Safety, Tolerability (all cohorts) and Efficacy (cohort 3), of once-a-month long-acting SC injection of dose escalating Cariprazine Depot in subjects eligible for treatment with oral Cariprazine.
This description comes directly from the study's public registry record.
Mark Weiser, Prof. · 97236973776 · CarD@mapi-pharma.com
Always discuss trial participation with your own doctor first.
| Mapi Pharma Investigational Site IN-101 | Ahmedabad, India | Recruiting |
| Mapi Pharma Investigational Site IN-102 | Ahmedabad, India | Recruiting |
| Mapi Pharma Investigational Site IL-004 | Beersheba, Israel | Recruiting |
| Mapi Pharma Investigational Site IL-003 | Ness Ziona, Israel | Recruiting |
| Mapi Pharma Investigational Site IL-005 | Ramat Gan, Israel | Recruiting |
| Mapi Pharma Investigational Site IL-001 | Tel Aviv, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07185815